The first 60 days: Non-muscle-invasive bladder cancer
Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG. Below, week by week, is what OnCo's record of Non-muscle-invasive bladder cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Cystoscopy, transurethral resection with muscle in the specimen, blue-light or enhanced imaging for carcinoma in situ; re-resection of T1 tumours.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- RadiologistNamed in the standard of care for: Diagnosis and resection.
- SurgeonNamed in the standard of care for: Diagnosis and resection, Low risk, Intermediate and high risk, BCG-unresponsive.
- Medical oncologistNamed in the standard of care for: Low risk, Intermediate and high risk, BCG-unresponsive.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Low risk.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
- 1.Low risk
Single immediate instillation of mitomycin or gemcitabine after resection; surveillance cystoscopy.
Induction and one to three years of maintenance BCG; intravesical chemotherapy when BCG is unavailable; early cystectomy for the highest-risk T1 disease.
Radical cystectomy, or bladder-sparing treatment: pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept with BCG, TAR-200, cretostimogene in trials and early approvals.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Grade and stage, Carcinoma in situ and lymphovascular invasion, FGFR3 mutations, Urinary biomarkers and cytology for surveillance, Molecular subtypes under study), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Low-grade Ta papillary tumours, High-grade Ta and T1 tumours, Carcinoma in situ.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Diagnosis and resection
- For my situation (diagnosis and resection), which of the standard options do you recommend and why?Guideline options include: Cystoscopy, transurethral resection with muscle in the specimen, blue-light or enhanced imaging for carcinoma in situ; re-resection of T1 tumours.
Low risk
- For my situation (low risk), which of the standard options do you recommend and why?Guideline options include: Single immediate instillation of mitomycin or gemcitabine after resection; surveillance cystoscopy.
- Am I a candidate for Mitomycin C, Gemcitabine, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Intermediate and high risk
- For my situation (intermediate and high risk), which of the standard options do you recommend and why?Guideline options include: Induction and one to three years of maintenance BCG; intravesical chemotherapy when BCG is unavailable; early cystectomy for the highest-risk T1 disease.
BCG-unresponsive
- For my situation (bcg-unresponsive), which of the standard options do you recommend and why?Guideline options include: Radical cystectomy, or bladder-sparing treatment: pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept with BCG, TAR-200, cretostimogene in trials and early approvals.
- Am I a candidate for Pembrolizumab, Nadofaragene firadenovec, Nogapendekin alfa inbakicept or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Gemcitabine intravesical system (TAR-200), Cretostimogene grenadenorepvec?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Recurrent BCG shortages”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Predicting who will progress to muscle invasion”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Non-muscle-invasive bladder cancer: the full pageMost bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Radical cystectomy: Removing the bladder (and nearby organs) for bladder cancer that has grown into the muscle wall; urine is then diverted through a stoma or a new bladder made of bowel.
Every term links to the glossary.